Pharmacogenetics: ethnicity, treatment and health in Latin American populations.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-06-01 DOI:10.2217/pgs-2023-0098

Martha Sosa-Macías, Ingrid Fricke-Galindo, Humberto Fariñas, Lucero Monterde, Eugenia Dolores Ruiz-Cruz, Juan Molina-Guarneros, Eduardo Tarazona-Santos, Fernanda Rodrigues-Soares, Carlos Galaviz-Hernández, Eva Peñas-Lledó, Graciela Moya, Julio Lara-Riegos, Enrique Terán, Isabel Hernández, Ronald Ramírez-Roa, Catalina Altamirano-Tinoco, Marisol López-López, José Elías García-Ortiz, Adrián LLerena

{"title":"Pharmacogenetics: ethnicity, treatment and health in Latin American populations.","authors":"Martha Sosa-Macías, Ingrid Fricke-Galindo, Humberto Fariñas, Lucero Monterde, Eugenia Dolores Ruiz-Cruz, Juan Molina-Guarneros, Eduardo Tarazona-Santos, Fernanda Rodrigues-Soares, Carlos Galaviz-Hernández, Eva Peñas-Lledó, Graciela Moya, Julio Lara-Riegos, Enrique Terán, Isabel Hernández, Ronald Ramírez-Roa, Catalina Altamirano-Tinoco, Marisol López-López, José Elías García-Ortiz, Adrián LLerena","doi":"10.2217/pgs-2023-0098","DOIUrl":null,"url":null,"abstract":"<p><p>The Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF) studies Latin American populations to benefit from the implementation of personalized medicine. Since 2006, it has studied ethnicity to apply pharmacogenetics knowledge in autochthonous populations of Latin America, considering ancestral medicine. The meeting 'Pharmacogenetics: ethnicity, Treatment and Health in Latin American Populations' was held in Mexico City, Mexico, and presented the relevance of RIBEF collaboration with Latin American researchers and the governments of Mexico, Spain and the Autonomous Community of Extremadura. The results of 17 years of uninterrupted work by RIBEF, the Declaration of Mérida/T'Hó and the call for the Dr José María Cantú Award for studies focused on the pharmacogenetics of native populations in Latin America were presented.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0098","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 2

Abstract

The Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF) studies Latin American populations to benefit from the implementation of personalized medicine. Since 2006, it has studied ethnicity to apply pharmacogenetics knowledge in autochthonous populations of Latin America, considering ancestral medicine. The meeting 'Pharmacogenetics: ethnicity, Treatment and Health in Latin American Populations' was held in Mexico City, Mexico, and presented the relevance of RIBEF collaboration with Latin American researchers and the governments of Mexico, Spain and the Autonomous Community of Extremadura. The results of 17 years of uninterrupted work by RIBEF, the Declaration of Mérida/T'Hó and the call for the Dr José María Cantú Award for studies focused on the pharmacogenetics of native populations in Latin America were presented.

查看原文本刊更多论文

药物遗传学:拉丁美洲人口的种族、治疗和健康。

伊比利亚-美洲药物遗传学和药物基因组学网络(RIBEF)研究拉丁美洲人群从个性化医疗的实施中受益。自2006年以来，它一直在研究种族，将药物遗传学知识应用于拉丁美洲土著人群，考虑到祖先医学。“药物遗传学:拉丁美洲人口的种族、治疗和健康”会议在墨西哥墨西哥城举行，会议介绍了RIBEF与拉丁美洲研究人员以及墨西哥、西班牙和埃斯特雷马杜拉自治区政府合作的相关性。会上介绍了RIBEF 17年不间断工作的成果、《msamrida /T宣言》'Hó和呼吁设立jos博士奖María Cantú，以表彰以拉丁美洲土著人群药物遗传学为重点的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.